
Sanofi Acquires Biogen's Bioverativ
The $11.6-billion acquisition strengthens Sanofi's position in hematology and specialty medicines.
On March 8, 2018, Sanofi announced that it has acquired Bioverativ, Biogen’s hemophilia and blood disorders-focused company, for $105 per share in cash.
Initially
“The addition of Bioverativ provides us with a strong position in the large and growing hemophilia market and expands our presence in specialty care,” said Olivier Brandicourt, CEOß at Sanofi, in a company press release. “Through a series of three strategic transactions-the addition of Bioverativ, our planned acquisition of Ablynx and our agreement for fitusiran-we are well on our way to creating a leading franchise in the field of rare blood disorders.”
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.